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A B S T R A C T
Crimean-Congo hemorrhagic fever (CCHF) is a fatal viral disease that occurs in approximately 30
countries. It has the most extensive geographic range among the tick-borne viruses that affect human
health. Recently, a 6-year-old boy presented with complaints of fever, fatigue, and loss of appetite. He
revealed a history of tick bite in rural Istanbul three days prior to presentation. A hyperemiawas detected
at the site of the tick bite. Laboratory tests showed that alanine aminotransferase, aspartate
aminotransferase, lactate dehydrogenase, and creatine phosphokinase levels were elevated and that the
prothrombin time and activated partial thromboplastin timewere prolonged. Anti-CCHF virus IgM ELISA
and a reverse transcriptase-PCR assay for CCHF RNA were both positive. Phylogenetic studies revealed
that the virus was a new AP92-like CCHF strain, which was named KMAG-Hu-07-01 (accession number
EU057975). This patient could provide important information on the transmission dynamics of CCHF
infection.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Crimean-Congo hemorrhagic fever (CCHF) is a fatal disease
caused by a Nairovirus of the family Bunyaviridae.1 The virus is
transmitted to humans through the bites of infected ticks or from
direct contact with viremic animals or humans.2 Isolation of CCHF
virus and/or CCHF disease have been reported in more than 30
countries in Africa, Asia, southeastern Europe, and the Middle
East.3,4 This disease is also an important public health issue in
Turkey. The ﬁrst cases in Turkeywere detected in the town of Tokat
in the Kelkit Valley region in the northern part of the country
(Figure 1) in 2002.5,6
Between 2002 and 2008, a total of 2508 conﬁrmed cases,
including 133 deaths, were reported to the Ministry of Health of
Turkey, with the number of cases increasing over the years.7 The
majority of cases (95%) were reported from middle and eastern
Anatolia, particularly from the cities of Tokat, Sivas, Yozgat, C¸orum,
and Erzurum.8 Sporadic cases have been reported from the
southeastern and western parts of Turkey as well.
To date, all of the CCHF cases detected in Istanbul have been
imported cases in which the patients had become infected outside
of Istanbul. Herein, we report a mild infection with a newly
emerged CCHF strain in Turkey. The strain was named KMAG-Hu-* Corresponding author. Tel.: +90 212 6330077; fax: +90 212 6326832.
E-mail address: drcivilibal@hotmail.com (M. Civilibal).
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.07.01707-01. This new strain is closely related to the AP92 strain, which
has only been detected in ticks in Greece.9,10
2. Case report
A previously healthy 6-year-old boy, living in the
Ku¨c¸u¨kc¸ekmece neighborhood in Istanbul, was admitted to Haseki
Education and Research Hospital with complaints of fever, fatigue,
and loss of appetite. The patient had been bitten by a tick on his
head three days earlier, when he had attended a picnic in the rural
Balkan area (Arnavutko¨y-Tas¸oluk region) of Istanbul. The boy’s
father had removed the tick on the day of the bite.
On admission, the patient appeared well. His body temperature
was 39 8C. His blood pressure was 95/60 mmHg and his pulse was
92 beats/min. His weight and height were at the 25th and 50th
percentiles, respectively. A hyperemia was detected on his scalp.
There was no hepatosplenomegaly, lymphadenopathy, petechiae,
or ecchymoses. The results of the respiratory, cardiovascular,
gastrointestinal, and neurological examinations were completely
normal. Laboratory test results were as follows: white blood cell
(WBC) count 6.1  109/l, red blood cell (RBC) count 4.84  1012/l,
platelet count 175  109/l, hemoglobin level 11.3 g/dl, erythrocyte
sedimentation rate 10 mm/h, and C-reactive protein 3 mg/dl.
Enzyme levels were elevated: alanine aminotransferase (ALT) 89
U/l (normal <40 U/l), aspartate aminotransferase (AST) 263 U/l
(normal <40 U/l), lactate dehydrogenase (LDH) 547 U/l (normal
125–243 U/l), and creatine phosphokinase (CK) 7690 U/l (normalses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Location where new the CCHF strain was acquired in Istanbul relative to the previously identiﬁed endemic zone (Kelkit Valley region of Turkey).
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thromboplastin time (aPTT) were prolonged at 20.1 s and 43.7 s,
respectively.
The patient was deﬁned as a suspected CCHF case based on the
history of a tick bite, the clinical symptoms, and the laboratory
ﬁndings. He was isolated in a single room and contact isolationFigure 2. Phylogenetic trees for CCHF strains. I: West Africa; II: Democratic Republic of C
(AP92). Previous isolates from Turkey and the new KMAG-Hu-07-01 virus are highlighprocedures were implemented. Supportive therapy consisted of
hydration and delivery of fresh frozen plasma. To deﬁnitively
diagnose the patient with CCHF, whole blood samples were drawn
into EDTA-containing vacutainer tubes on the third day after
admission. The blood samples were sent to the local and national
reference laboratories: the Microbiology and Clinical Microbiologyongo; III: Southern/West Africa; IV: Asia/Middle East; V: Europe/Turkey; VI: Greece
ted on the tree.
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(local) and the Virology Laboratory of the Reﬁk Saydam Hygiene
Center in Ankara (national). Serologic testing for anti-CCHF virus
IgM and IgG was done by ELISA. IgM antibodies speciﬁc for CCHF
virus were found. Anti-CCHF virus IgG was absent. Molecular data
were also obtained by real-time reverse transcriptase-PCR (RT-
PCR). RNA was extracted from 200 ml of whole blood using a
commercial RNA extraction kit (High Pure Viral Nucleic Acid Kit,
Roche Diagnostics, Germany) and cDNA synthesized using the
Omniscript reverse transcription kit (Qiagen, Germany), according
to themanufacturer’s instructions. RT-PCR for CCHF virus RNAwas
positive. In the design of the primers used during the diagnostic
screening for CCHF virus RNA, all S segment sequences fromTurkey
and from several eastern European countries were downloaded
from GenBank and were aligned using the Clustal Wallis software
program. Primers for the S segment of the virus were selected for
the ﬁrst and second rounds of ampliﬁcation. The sites of the
possible primers were selected visually and were evaluated using
the Primer test option of the Primer Express software (Applied
Biosystems, USA). After the initial diagnostic PCR, the amplicon
was sequenced. The obtained sequence closely matched the
sequence of the AP92 strain. For exclusive ampliﬁcation of
AP92-strain RNA, we chose primers from the S segment of this
strain. For molecular analyses and comparisons, a 439-bp segment
(between nucleotides 218 and 657, numbered according the AP92
strain (U04958)) of the S segment was used. Phylogenetic analysis
of the obtained sequence of the new CCHF virus revealed that the
strain is closely related to the AP92 strain, which has been found in
Greece. The nucleotide sequence divergence between the new
strain and AP92 was 17.43% (200/218 nt). However, at the amino
acid sequence level (146 amino acids), the two strains differed only
at two positions (1.36%). The sequence of the new Turkish strain
was deposited in GenBank under the accession number EU057975.
The strain was named KMAG-Hu-07-01 (Figure 2).
On the day of admission, ribavirin was not administered
because it was not available. The patient’s symptoms, PT and aPTT
had already improved on the second day of hospitalization. No
hemorrhagic signs were observed during the course of the disease,
and all abnormal laboratory test results (ALT, AST, LDH, and CK)
returned to normal by day 10. The childwas deﬁned as amild CCHF
case and was discharged with complete recovery.
3. Discussion
Crimean hemorrhagic fever was ﬁrst described in 1944, when
approximately 200 Soviet military personnel were infected in
Crimea in the wake of World War 2. The virus was identiﬁed in
1967 and was found to be similar to a virus isolated in 1956 from a
febrile patient in Congo. The virus was then named Crimean-Congo
hemorrhagic fever virus.11 Over the last decade, climate, environ-
mental, and anthropogenic factors have driven the expansion of
CCHF-endemic areas and have triggered the onset of community
outbreaks.12 Such outbreaks were recorded in Turkey in 2002–
2008.4–8 In April 2008, a cluster of suspected CCHF cases occurred
in southern Bulgaria, a few kilometers from the border with
Greece.13 Turkey and all Balkan countries with the exception of
Greece have recorded the circulation of CCHF strains among animal
hosts, ticks, and humans, and CCHF is considered to be endemic in
these countries.14 The wide outbreaks that occurred in Turkey
were preceded by several decades of serologic evidence of zoonotic
transmission of CCHF.12 In previous studies,4–8 all of the CCHF
patients identiﬁed in Istanbul were imported cases; that is, they
had been infected outside of Istanbul. The present patient was the
ﬁrst CCHF case to be infected within the city.
The typical course of CCHF infection has four distinct phases:
incubation (3–7 days), pre-hemorrhagic (4–5 days), hemorrhagic(2–3 days), and convalescence (10–20 days). The pre-hemorrhagic
period is characterized by the sudden onset of fever (39–41 8C),
headache, myalgia, and dizziness. The hemorrhagic period is short
and usually begins between the third and ﬁfth days of the disease.
Hemorrhagicmanifestations range frompatchy to largehematomas
appearing on themucousmembranes and the skin. Our patient was
within the pre-hemorrhagic period when admitted and presented
with complaints of fever, fatigue, and loss of appetite. The clinical
and laboratory ﬁndings showed that the casewasmild according to
the severity criteria deﬁned by Ergonul et al.15
In 1967, when the virus was ﬁrst named CCHF virus,11 the
antigenic structures of the viruses from various geographic regions
were thought to be indistinguishable. However, nucleic acid
sequence analysis has since revealed extensive genetic diversity.
All previously identiﬁed Turkish CCHF virus isolates from the
recent outbreak have clustered closelywith CCHF viral strains from
southwest Russia and the Balkan countries (lineage V in Figure 2).
The strains from southeast Russia are closely related to the
European strains. Because of their low genetic divergence, the
European strains are grouped together, except for the Greek AP92
strain.9,10 The AP92 strain, isolated from Rhipicephalus bursa ticks
in Greece, differs from European strains and forms a very distinct
clade, quite separate from the other CCHF virus lineages. This
genetic difference may be attributable to the different species of
tick vector and/or to genetic isolation due to the intervening
mountain ranges.9
In this report, we have described a newly identiﬁed CCHF strain
from Turkey. This strain of CCHF was found in a different area of
Turkey than previously identiﬁed Turkish strains, and the new
strain is genetically quite different from those found previously in
Turkey. It is closely related to the AP92 virus found previously only
in Rhipicephalus bursa ticks in Greece.
The current treatment approach for CCHF is based on general
supportive measures, monitoring the patient’s hematologic and
coagulation status, with replacement of cells and factors as needed,
and the use of ribavirin.16 Ribavirin is the recommended antiviral
agent for infected patients, although its mechanism of action is not
clear. It should be noted that there is no evidence from randomized
clinical trials to support the use of ribavirin to treat human CCHF,
and ribavirin’s effectiveness has only been described in observa-
tional studies.4 A recent study suggested that mild cases do not
need to be treated with ribavirin.17 On admission, ribavirin could
not be given to our patient because it was not available. Thereafter,
it was not administered to the patient, since his case was
subsequently deﬁned as mild.
In conclusion, this study describes a case of CCHF infection in a
child, caused by a virus strain closely related to the AP92 strain. The
newly identiﬁed strain of CCHF is genetically quite different from
strains previously found in Turkey. It is closely related to the AP92
virus previously found only in Greece. The fact that the infection
wasmost likely acquired in the rural Balkan part of Istanbul is even
more interesting. This new focus of infection could present a good
opportunity to describe the transmission dynamics of CCHF
infection.
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